Kenya - English - Pharmacy and Poisons Board

empagliflozin 25mg - film-coated tablet - empagliflozin 25mg - empagliflozin

Kenya - English - Pharmacy and Poisons Board

martin dow limited plot no. 37, sector 19, korangi industrial area, - empagliflozin 25mg - coated tablet - empagliflozin 25mg - empagliflozin

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - empagliflozin 25mg;  ;   - film coated tablet - 25 mg - active: empagliflozin 25mg     excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 02b38190 - type 2 diabetes mellitus glycaemic control: jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults and children aged 10 years and above as: monotherapy - when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. add-on combination therapy - in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see further information in section 5.1).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 5 mg; empagliflozin, quantity: 25 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; mannitol; crospovidone; titanium dioxide; magnesium stearate; copovidone; pregelatinised maize starch; macrogol 6000; iron oxide red; maize starch - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - empagliflozin, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; hyprolose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - type 2 diabetes mellitus,glycaemic control,jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as:,monotherapy,when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.,add-on combination therapy,in combination with other glucose?lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 5.1 pharmacodynamic properties - clinical trials).,prevention of cardiovascular death,jardiance is indicated in patients with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, jardiance should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.,heart failure,jardiance is indicated in adults for the treatment of symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy (see section 5.1 pharmacodynamic properties - clinical trials).,chronic kidney disease,jardiance is indicated to reduce the risk of kidney disease progression in adults with chronic kidney disease (ckd stages 2 and 3a with urine acr ?30 mg/g, or ckd stages 3b, 4 and 5 irrespective of urine acr).

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2) - empagliflozin 10 mg - glyxambi is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies (14.2)] . limitations of use glyxambi is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi [see warnings and precautions (5.2)]. glyxambi is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m2 . glyxambi is likely to be ineffecti

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - empagliflozin 5 mg - synjardy synjardy is a combination of empagliflozin and metformin hydrochloride (hcl) indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. synjardy xr synjardy xr is a combination of empagliflozin and metformin hcl indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. empagliflozin empagliflozin, when used as a component of synjardy or synjardy xr, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: - cardiovascular death in adults with established cardiovascular disease. - cardiovascular death and hospitalization for heart failure in adults with heart failure. limitations of use - synjardy and synjardy xr are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.2)] . - because

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - empagliflozin 10 mg - synjardy synjardy is a combination of empagliflozin and metformin hydrochloride (hcl) indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. synjardy xr synjardy xr is a combination of empagliflozin and metformin hcl indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. empagliflozin empagliflozin, when used as a component of synjardy or synjardy xr, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: - cardiovascular death in adults with established cardiovascular disease. - cardiovascular death and hospitalization for heart failure in adults with heart failure. limitations of use - synjardy and synjardy xr are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.2)] . - because

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 25 mg - linagliptin and empagliflozin - jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الادوية العربي - the arab drug store p.s.c - empagliflozin 25 mg - 25 mg